“Glenmark Pharmaceuticals, USA, has been granted tentative approval by the US Food and Drug Administration (USFDA) for adapalene and benzoyl peroxide gel, 0.1%/ 2.5%,” it said in a BSE filing today.
Adapalene and benzoyl peroxide gel is generic version of Galderma Laboratories LP’s Epiduo.
According to IMS Health sales data for the 12 months to February 2016, Glenmark said Epiduo gel achieved annual sales of around$ 351.8 million.
The company’s current portfolio consists of 112 products authorised for distribution in the US marketplace and 58 ANDA pending approvals with USFDA.
The stock was trading 0.98% up at Rs 826.50 in the morning trade on BSE.
The original article is at: business-standard.com